| Literature DB >> 30466493 |
Toshikazu Abe1,2, Hiroshi Ogura3, Atsushi Shiraishi4, Shigeki Kushimoto5, Daizoh Saitoh6, Seitaro Fujishima7, Toshihiko Mayumi8, Yasukazu Shiino9, Taka-Aki Nakada10, Takehiko Tarui11, Toru Hifumi12, Yasuhiro Otomo13, Kohji Okamoto14, Yutaka Umemura3, Joji Kotani15, Yuichiro Sakamoto16, Junichi Sasaki17, Shin-Ichiro Shiraishi18, Kiyotsugu Takuma19, Ryosuke Tsuruta20, Akiyoshi Hagiwara21, Kazuma Yamakawa22, Tomohiko Masuno23, Naoshi Takeyama24, Norio Yamashita25, Hiroto Ikeda26, Masashi Ueyama27, Satoshi Fujimi22, Satoshi Gando28.
Abstract
BACKGROUND: Sepsis is a leading cause of death and long-term disability in developed countries. A comprehensive report on the incidence, clinical characteristics, and evolving management of sepsis is important. Thus, this study aimed to evaluate the characteristics, management, and outcomes of patients with severe sepsis in Japan.Entities:
Keywords: Bundle; Elderly; Resuscitation; Sepsis
Mesh:
Year: 2018 PMID: 30466493 PMCID: PMC6251147 DOI: 10.1186/s13054-018-2186-7
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Demographic, infection, and admission characteristics of patients with severe sepsis (n = 1184)
| Characteristics | |
|---|---|
| Age at admission, years | 73 (64–81) |
| Male | 719/1184 (60.7) |
| BMI, kg/m2 | 22 (19–25) |
| Admission source | |
| ED | 676 (57.2) |
| non-ED (hospital/department transfers) | 457 (38.7) |
| ICU | 49 (4.1) |
| Coexisting conditions | |
| Myocardial infarction | 58 (4.9) |
| Congestive heart failure | 128 (10.8) |
| Peripheral vascular disease | 29 (2.4) |
| Cerebrovascular disease | 140 (11.8) |
| Dementia | 97 (8.2) |
| COPD | 82 (6.9) |
| Connective tissue disease | 83 (7.0) |
| Peptic ulcer disease | 32 (2.7) |
| Diabetes mellitus without organ damage | 197 (16.6) |
| Diabetes mellitus with organ damage | 75 (6.3) |
| Chronic kidney disease | 85 (7.2) |
| Hemiplegia | 44 (3.7) |
| Malignancy (solid) | 161 (13.6) |
| Malignancy (blood) | 23 (1.9) |
| Metastatic tumor | 26 (2.2) |
| Mild liver disease | 46 (3.9) |
| Moderate to severe liver disease | 26 (2.2) |
| AIDS | 1 (0.1) |
| CCI | |
| 0 | 391 (33.0) |
| 1–2 | 542 (45.8) |
| 3–4 | 182 (15.4) |
| > 4 | 69 (5.8) |
| ADL | |
| Dependent | 288 (24.3) |
| Suspected site of infection | |
| Lung | 367 (31.0) |
| Abdomen | 311 (26.3) |
| Urinary tract | 218 (18.4) |
| Soft tissue | 117 (9.9) |
| Central nervous system | 23 (1.9) |
| IV catheter | 22 (1.9) |
| Osteoarticular | 21 (1.8) |
| Endocardium | 16 (1.4) |
| Wound | 12 (1.0) |
| Implant device | 8 (0.7) |
| Other | 69 (5.8) |
| Positive blood cultures | 636 (54.0) |
| Septic shock | |
| Yes | 745 (62.9) |
| Organ dysfunction on arrival | |
| Hypotension | 656 (55.4) |
| Hyperlactatemia (> 2 mmol/L) | 797 (67.3) |
| Acute kidney injury (Cre > 2 mg/dL) | 455 (38.4) |
| Acute lung injury | 442 (37.3) |
| Hyperbilirubinemia (> 2.0 mg/dL) | 204 (17.2) |
| Thrombocytopenia (< 100,000/μL) | 345 (29.1) |
| Coagulopathy (INR > 1.5) | 225 (19.0) |
| ARDSa at 1st day | 193 (18.0) |
| qSOFA score | 2 (1–3) |
| qSOFA ≥ 2 | 800 (69.6) |
| APACHE II score | 23 (17–29) |
| SIRS score | 3 (2–4) |
| SOFA score | 9 (6–11) |
| SOFA score ≥ 2 | 987 (98.6) |
Reported counts (proportions) for categorical variables and median (interquartile range) for continuous variables
Missing data: body mass index (BMI) = 26, admission source = 2, insurance = 2, activities of daily living (ADL) = 2, blood culture = 7, acute respiratory distress syndrome (ARDS) = 112, quick Sepsis-related Organ Failure Assessment (qSOFA) = 35, Acute Physiology and Chronic Health Evaluation (APACHE) II = 162, systemic inflammatory response syndrome (SIRS) = 43, SOFA = 183
ED emergency department, CCI Charlson Comorbidity Index, COPD chronic obstructive pulmonary disease, AIDS acquired immune deficiency syndrome, IV intravenous
aARDS was defined by Berlin criteria
Organizational characteristics in the FORECAST study
| Characteristics | Number (%) of ICUs | Number (%) of patients |
|---|---|---|
| 59 | 1184 | |
| Facility | ||
| Type of ICU | ||
| Open | 36 (61.0) | 594 (50.2) |
| Closed | 23 (39.0) | 590 (49.8) |
| ICU specialty | ||
| Medical | 3 (5.1) | 78 (6.6) |
| Mixed | 56 (94.9) | 1106 (93.4) |
| Number of ICU beds | ||
| 1–10 | 25 (42.4) | 363 (30.7) |
| 11–20 | 26 (44.1) | 580 (50.0) |
| ≥ 21 | 8 (13.6) | 241 (20.4) |
| Number of hospital beds | ||
| ≤ 500 | 13 (22.0) | 185 (15.6) |
| 501–900 | 31 (52.5) | 637 (53.8) |
| ≥ 901 | 15 (25.4) | 362 (30.6) |
| Type of hospital | ||
| Non-university | 30 (50.8) | 458 (38.7) |
| University | 29 (49.2) | 726 (61.3) |
| Staff | ||
| Number of board-certificated intensivists | ||
| 0 | 14 (23.7) | 211 (17.8) |
| 1 | 16 (27.1) | 243 (20.5) |
| ≥ 2 | 29 (49.2) | 730 (61.7) |
| Number of board certificated emergency physicians | ||
| 0–4 | 17 (28.8) | 167 (14.1) |
| 5–8 | 22 (37.3) | 321 (27.1) |
| ≥ 9 | 20 (33.9) | 696 (58.8) |
| Number of ICU nurses | ||
| ≤ 40 | 29 (49.2) | 584 (49.3) |
| > 40 | 30 (50.8) | 600 (50.7) |
| Nurse to bed ratio in each shift | ||
| 1:2 | 50 (84.7) | 1052 (88.9) |
| 1:4 | 9 (15.3) | 132 (11.1) |
| Patients | ||
| Number of emergency patients (2014) ( | ||
| ≤ 4000 | 14 (28.0)) | 293 (28.8) |
| 4001–18,000 | 23 (46.0) | 509 (50.0) |
| ≥18,001 | 13 (26.0) | 216 (21.2) |
| Number of ambulance patients (2014) ( | ||
| ≤ 2000 | 15 (30.0) | 313 (30.7) |
| 2001–5000 | 20 (40.0) | 295 (29.0) |
| ≥ 5001 | 15 (30.0) | 410 (40.3) |
| Number of ICU patients (2013) ( | ||
| ≤ 500 | 15 (25.9) | 216 (18.2) |
| 501–1000 | 28 (48.3) | 642 (54.2) |
| ≥ 1001 | 15 (25.9) | 326 (27.5) |
ICU intensive care unit
Microbiologic blood culture results and initial antibiotics use among patients with severe sepsis
| Microbiological results of blood cultures | |
| Gram-negative | |
| | 182 (32.5) |
| Klebsiella | 72 (12.9) |
| Pseudomonas | 16 (2.9) |
| Gram-positive | |
| Staphylococci | 91 (16.3) |
| Streptococci | 109 (19.5) |
| MRSA | 16 (2.9) |
| Enterococcus | 25 (4.5) |
| Anaerobic | 24 (4.3) |
| Fungi | 14 (2.5) |
| Antibiotics | |
| Penicillin derivative (PCG, ABPC, ABPC/MCIPC) | 30 (2.6) |
| Ampicillin/sulbactam | 78 (6.8) |
| PIPC/TAZ | 238 (20.9) |
| Sulbactam/cefoperazone | 11 (1.0) |
| First-generation cephalosporin | 28 (2.5) |
| Second-generation cephalosporin (CTM, CMZ, FMOX) | 32 (2.8) |
| Third-generation cephalosporin (CTX, CPZ, CTRX) | 99 (8.7) |
| Third-generation cephalosporin against pseudomonas | 4 (0.4) |
| Fourth generation cephalosporin against pseudomonas | 26 (2.3) |
| Carbapenem | 627 (55.0) |
| Aminoglycoside | 8 (0.7) |
| Quinolone | 19 (1.7) |
| Tetracycline | 7 (0.6) |
| Macrolide | – |
| Metronidazole | 12 (1.1) |
| CLDM | 48 (4.2) |
| Vancomycin | 203 (17.8) |
| Other anti-methicillin-resistant | 67 (5.9) |
| Antifungals | 50 (4.4) |
| Others | 83 (7.3) |
Reported counts (proportions). Missing data: microbiology data = 76, antibiotics = 44. There was no intravenous macrolide during the study period in Japan
PCG penicillin G, ABPC ampicillin, ABPC/MCIPC ampicillin/cloxacillin, PIPC/TAZ tazobactam/piperacillin, CTM cefotiam, CMZ cefmetazole, FMOX flomoxef, CTX cefotaxime, CPZ cefoperazone, CTRX ceftriaxone, CLDM clindamycin, CNS central nervous system
Achievement of Surviving Sepsis Campaign bundle targets in 59 ICUs, Japan (n = 1184)
| Compliance rate | |
|---|---|
| Compliance with all applicable elements of sepsis 3-h bundle | |
| Entire 3-h resuscitation bundlea | 543/844 (64.3) |
| B1. Serum lactate obtained | 1143/1180 (96.9) |
| B2. Broad-spectrum antibiotic given | 985/1179 (83.5) |
| B3. Blood cultures obtained before broad-spectrum antibiotic administration | 1084/1178 (92.0) |
| B4. 30 mg/kg crystalloid fluid bolus delivered (yes/cases with indication)a | 645/845 (76.3) |
| Compliance with all applicable elements of sepsis 6-h bundle | |
| Entire 6-h resuscitation bundleb | 41/688 (3.5) |
| Vasopressors use + re-measured lactate | 625/752 (83.1) |
| B5. Vasopressor use followed initial fluid bolus if needed to maintain MAP ≥ 65 mmHg (yes/cases with indication) | 745/841 (88.6) |
| B6. CVP measured (yes/cases with indication)a | 225/856 (26.3) |
| B7. CVP 8 mmHg achieved (yes/cases with indication)a | 181/227 (79.7) |
| B8. ScvO2 measured (yes/cases with indication)a | 60/853 (7.0) |
| B9. ScvO2 70% (or SvO2 65%) achieved (yes/cases with indication)a | 49/66 (74.2) |
| B10. Re-measured lactate if initial lactate elevated (yes/cases with indication) | 864/960 (90.0) |
| Entire 3-h resuscitation bundle + vasopressors use + re-measured lactate | 397/693 (57.3) |
| Entire 3-h resuscitation bundle + vasopressors use | 449/750 (59.9) |
Reported counts (proportions). Missing data: B1 = 4, B2 = 5, B3 = 6, B4 = 9, B5 = 7, B6 = 10, B7 = 757, B8 = 9, B9 = 899, B10 = 14
MAP mean arterial pressure, CVP central venous pressure, ScvO2 central venous oxygen saturation, SvO2 mixed venous oxygen saturation, ICU intensive care unit
aSeptic shock or lactate > 4 mmol/L
bExcluded the achievement of a CVP of 8 mmHg and a ScvO2 of 70% from the entire 6-h bundle analysis
A multilevel logistic model for achievement of the entire 3-h resuscitation bundle among ICUs in the FORECAST study
| Characteristics | Odds_(95%CI) |
|---|---|
| Type of ICU | |
| Closed | 2.84_(1.28–6.28) |
| Number of ICU beds | |
| 1–10 | |
| 11 to 20 | 0.88_(0.38–2.08) |
| ≥ 21 | 1.57_(0.44–5.6) |
| Type of hospital | |
| University | 0.35_(0.15–0.78) |
| Number of board-certified intensivists | |
| 0 | |
| 1 | 0.7_(0.25–1.95) |
| ≥ 2 | 0.62_(0.24–1.64) |
| ICU nurse ratio | |
| 1:2 | 1.24_(0.41–3.75) |
| Number of ICU patients per year | |
| 0–500 | |
| 501–1000 | 1.22_(0.48–3.14) |
| ≥ 1001 | 2.18_(0.61–7.78) |
ICU intensive care unit
Outcomes among patients with severe sepsis (n = 1184)
| Outcomes | |
|---|---|
| In-hospital mortality | 269/1148 (23.4 (21.0–26.0)%) |
| with shock ( | 200/718 (27.9 (24.6–31.3)%) |
| Survivor disposition | |
| Home | 323/879 (36.7) |
| Transfer | 556/879 (63.3) |
| ICU-free days | 19 (11–24) |
| Ventilator-free days | 21 (0–28) |
| Length of hospital stay | 24 (12–46) |
Reported counts (proportions) for categorical and median (interquartile range) for continuous variables
Missing data: in-hospital mortality=36, ICU free days=263, Ventilator free days=47
ICU intensive care unit
Fig. 1Survival probability during the first 80 days for patients with severe sepsis (n = 1043)
Relationship between epidemiological and treatment factors and in-hospital mortality among patients with severe sepsis using a generalized estimating equation model (n = 952)
| Characteristics | Odds_(95%CI) |
|---|---|
| Age at admission, years | 1.02_(1.01–1.04) |
| Male sex | 0.81_(0.57–1.14) |
| Body mass index | 1_(0.97–1.04) |
| ADL | 0.88_(0.58–1.32) |
| Admission source | |
| ED | reference |
| w/o ED (transfer or other department) | 1.12_(0.78–1.62) |
| ICU | 1.99_(0.91–4.36) |
| CCI | 1.2_(1.09–1.32) |
| Septic shock | |
| Yes | 1.01_(0.63–1.62) |
| Suspected site of infection | |
| Lung | reference |
| Abdomen | 0.54_(0.35–0.85) |
| Urinary tract | 0.22_(0.12–0.41) |
| Soft tissue | 0.73_(0.4–1.33) |
| Others | 1.16_(0.7–1.89) |
| SOFA score | 1.18_(1.12–1.24) |
| Positivity of blood cultures (bacteremia) | 1.16_(0.82–1.64) |
| Fluid resuscitation protocola | |
| Not achievement | reference |
| Achievement | 1.14_(0.72–1.82) |
| Not indicated | 1.06_(0.59–1.91) |
| Broad-spectrum antibiotic use | 1.04_(0.66–1.64) |
Missing data: body mass index = 26, admission source = 2, ADL = 2, positivity of blood cultures = 7, Sepsis-related Organ Failure Assessment (SOFA) = 183, fluid resuscitation protocol = 9, broad-spectrum antibiotic use = 5
ED emergency department, ICU intensive care unit, CCI Charlson Comorbidity Index, ADL activities of daily living
aCrystalloid fluid bolus (30 mg/kg) delivered if it was indicated in the bundle in Surviving Sepsis Campaign Guidelines 2012